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ABSTRACT 
Purpose: The uterine tandem with open-ended vaginal cylinder is the most commonly used brachytherapy system 
for Federation Internationale de Gynecologie et d’Obstetrique (FIGO) Stage IIIA cervix cancer at the National Cancer 
Centre, Singapore. Without the 3-channel ovoid system, the dose to the parametrium is often compromised. In this study, 
a vaginal cylinder that could potentially be incorporated with the 3-channel system was developed, hence addressing the 
problem of treating both the vaginal disease extension and the parametrium.  
Methods and materials: A hollow cylinder of 3 cm in diameter was incorporated with the Fletcher’s 3-channel 
tandem and ovoid system. Treatment plans were generated with the single tandem line source with a vaginal cylinder 
applicator and the modified Fletcher’s system using the Abacus version 3 brachytherapy treatment planning software. A 
nominal dose of 5 Gy was prescribed to point H for both plans. The perpendicular distance of the 5 Gy isodose line from 
the uterine tandem plane at the centre of the ovoid and the vaginal cylinder plane 1 cm below the os guard were then 
compared.  
Results: The 5 Gy isodose line was 1.7 cm from the uterine tandem source at the location lateral through the centre 
of the ovoids on the plan with the uterine tandem and vaginal cylinder system as compared to a distance of 3.3 cm using 
the modified 3-channel Fletcher system. The 5 Gy isodose line was 2 cm lateral to the central source at the vaginal 
cylinder plane 1 cm below the os guard on the uterine tandem and vaginal cylinder system as compared to a distance of 
2.5  cm  on  the  Modified-Fletcher  system.  This  corresponds  to  an  increase  of  1.6  cm  and  0.5  cm  depth  of  treated 
parametrium on the uterine tandem plane and vaginal cylinder plane respectively with the modified Fletcher’s applicator 
as compared with the single line source cylinder system. 
Conclusion: As compared with the single uterine tandem and open-ended vaginal cylinder system, an addition of 
1.6 cm of the parametrium was covered within the 5Gy isodose on the uterine tandem plane and 0.5 cm on the vaginal 
cylinder plane with the modified Fletcher’s applicator. A feasibility study was started to address the ease of insertion of 
this modified Fletcher system into patients. © 2006 Biomedical Imaging and Intervention Journal. All rights reserved. 
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INTRODUCTION 
FIGO  IIIA  cervix  cancer  with  disease  extension 
down to lower third of vagina, without extension onto 
the pelvic sidewall or hydronephrosis is uncommon and 
constitutes  approximately  2%  to  3%  of  all  cervical 
cancers  [1,2].  The  current  standard  of  care  consists of 
external beam radiotherapy to the whole pelvis followed 
by  brachytherapy  (intracavitary  or  implants)  with 
concurrent  single  agent  cisplatin  chemotherapy.  The 
uterine  tandem  with  vaginal  cylinder  is  the  most 
commonly  used  brachytherapy  system  as  it  deals  with 
the disease extension onto the lower third of the vagina 
(Figure  1a).  The  Fletcher’s  3-channel  brachytherapy 
system  with  ovoids  is  not  used,  as  the  disease  in  the 
lower  vagina  cannot  be  addressed  (Figure  1b). 
Parametrial  disease  extension  and  discontinuous 
involvement of the vagina are poor prognostic features in 
stage III disease [2]. Without the 3-channel ovoid system, 
the  radiation  dose  to  the  parametrium  may  be 
compromised. In this study, a vaginal cylinder that could 
potentially  be  incorporated  with  the  3-channel  system 
was developed. This report is a pilot dosimetric study to 
assess the applicability of this new vaginal applicator.  
METHODS AND MATERIALS 
A hollow Perspex cylinder of 3 cm in diameter was 
fashioned. The ends of the cylinder were smoothened out 
to avoid injury to the vagina mucosa (Figure 2a). Two 
open ended rectangular shaped slits were fashioned at the 
end  of  the  cylinder  to  accommodate  the  ovoids.  The 
cylinder  was  then  incorporated  with  the  Fletcher’s 
tandem and ovoids systems (Figure 2b). The separation 
between the ovoids was set at 3.5 cm, the usual distance 
in the 3-channel brachytherapy treatment. The 3-channel 
brachytherapy with vaginal applicator was placed in air 
and  orthogonal  films  taken  in  the  simulator  for 
dosimetric calculation. Similarly, the open-ended vaginal 
 
(a) 
 
 
(b) 
 
Figure 1  (a) Uterine tandem with vaginal cylinder system. (b) Fletcher’s 3-channel system. 
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Figure 2  (a) Hollow Perspex cylinder fashioned in our workshop (rectangular slits to accommodate the ovoids). 
(b) Perspex cylinder incorporated into the 3-channel Fletcher’s system. JSH Low et al. Biomed Imaging Interv J 2006; 2(1):e15    3 
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cylinder  with  a  single  uterine  tandem  applicator  was 
placed in air for orthogonal films. The Abacus version 3 
brachytherapy  treatment  planning  system  for 
Gammamed  brachytherapy  machine  (Isotopen-Technik 
Dr Sauerwein GmBH) was used for dose calculation. A 
nominal dose of 5 Gy was prescribed to point H for both 
plans [3]. The separation between the sources was 5 mm 
apart. The HDR system was used and the basis of source 
loading was according to variable dwelt time generated 
by the Abacus 3 planning system (Isotopen-Technik Dr 
Sauerwein GmBH). The perpendicular distance of the 5 
Gy  isodose  line  from  the  uterine  tandem  plane  at  the 
centre of the ovoids and the vaginal cylinder plane 1 cm 
below the os guard were then compared to determine the 
amount  of  parametrial  tissue  covered  within  the  5  Gy 
volume between the two systems.  
RESULTS 
The distance of the 5 Gy isodose line was 1.7 cm 
from  the  uterine  tandem  source  at  the  location  lateral 
through  the  centre  of  the  ovoids  on  the  plan  with  the 
uterine tandem and vaginal cylinder system as compared 
with a distance of 3.3 cm using the modified 3-channel 
Fletcher system (Figure 3). Figure 4 shows the sagittal 
plane  of  the  isodose  distribution  for  the  modified  3-
channel system. The 5 Gy isodose line was 2 cm lateral 
to the central source at the vaginal cylinder plane 1 cm 
below the os guard on the uterine tandem and vaginal 
cylinder system as compared to a distance of 2.5 cm on 
the  Modified-Fletcher  system  (Figure  5).  This 
corresponds to an increase of 1.6 cm and 0.5 cm depth of 
treated  parametrium  on  the  uterine  tandem  plane  and 
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Figure 3  Distance of 5Gy isodose line from central source at Point H (uterine tandem plane 40° to horizontal). 
Scale: distance between adjacent points is 1 cm . (a) Flectcher’s 3-channel system. (b) Uterine tandem 
with cylinder system. 
 
 
 
Figure 4  Sagittal plane of isodose distribution for 3-channel system with vaginal line source. Scale: distance 
between adjacent points is 1cm. JSH Low et al. Biomed Imaging Interv J 2006; 2(1):e15    4 
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vaginal  cylinder  plane  respectively  with  the  modified 
Fletcher’s  applicator  as  compared  with  the  single  line 
source cylinder system. The results are summarised in 
Table 1.  
DISCUSSION 
3-channel uterine tandem with vaginal ovoids is the 
most commonly used brachytherapy system for cervical 
cancers. This treatment gives rise to the classical pear-
shaped  isodose  distribution  that  adequately  covers  the 
disease in the cervix and parametrium. Study has shown 
that  parametrial  disease  extension  and  discontinuous 
involvement of the vagina to be poor prognostic features 
in stage III disease [2]. Often the local disease failure in 
surgical treatment of cervix cancer is a lack of a clear 
margin in the parametrial sidewall. Radiotherapy has an 
advantage  over  surgery  especially  in  more  advanced 
stages of cervix cancer, as radiation is able to cover the 
parametrial  tissue  and  pelvic  sidewall  adequately  with 
external beam radiotherapy followed by a booster dose 
of  brachytherapy.  However,  in  Stage  IIIA  cancer  with 
disease  extension  onto  the  vagina,  single  line  source 
uterine tandem with open-ended vaginal cylinder is often 
used, as the Fletcher’s 3-channel system cannot deal with 
the  disease  in  the  vagina.  This  is  due  to  a  lack  of  an 
apparatus to prevent the vaginal mucosa from collapsing 
onto  the  central  tandem  source.  Although  parametrial 
boost using external beam photons can be used, they do 
not  have  the  advantage  of  rapid  fall-off  of  doses  and 
tissue sparing as compared with brachytherapy. There is 
also  a  risk  of  overlapping  of  the  parametrial  boost 
external beam with the brachytherapy treatment fields. A 
simple Perspex hollow cylinder was therefore fashioned 
in our workshop to be incorporated together with the 3-
channel  tandem-ovoid  system.  The  purpose  of  the 
Perspex vaginal cylinder is to hold the vagina mucosa 
away from the tandem source, hence keeping the tandem 
source in the centre of the vagina. This will enable the 
loading of sources in the tandem down to the vagina. The 
cervical, parametrial and vagina disease can be targeted 
simultaneously  with  this  modified  3-channel 
brachytherapy system.  
Comparing the isodose plans between the 2 systems, 
there was a 1.6 cm (uterine tandem plane, Figure 3) and a 
0.5 cm (vaginal cylinder plane, Figure 5) increase in the 
parametrial tissue covered within the 5 Gy isodose with 
this applicator as compared with the single line source 
uterine tandem with open-ended cylinder system.  
CONCLUSION 
This simple dosimetric study showed that by adding 
the vaginal Perspex cylinder applicator on the 3-channel 
Fletcher’s  system,  the  conventional  pear-shaped 
distribution of the isodoses is achieved along with the 
treatment of the disease extension onto the vagina at the 
same time. 
This may be especially helpful in patients with Stage 
IIIA  or  more  advanced  disease  with  a  combination  of 
parametrial and vaginal involvement. A feasibility study 
was  started  to  address  the  ease  of  insertion  of  this 
modified  Fletcher  system  into  patients  with  further 
modification as necessary before starting a perspective 
study on patients with Stage IIIA disease.  
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Figure 5  Distance of 5Gy isodose line from central source at vaginal cylinder plane. (a) Flectcher’s 3-channel 
system. (b) Uterine tandem with cylinder system. 
 
 
 
 
 
Table 1  Distance of 5 Gy isodose line from central source. 
Uterine tandem plane at centre of ovoids (Figure 3)  Left (cm)  Right (cm)  Mean (cm) 
Fletcher’s 3-channel  3.1  3.5  3.3 
Uterine tandem with vaginal cylinder  1.7  1.7  1.7 
 
Vaginal cylinder plane 1 cm below os guard (Figure 4)  Left (cm)  Right (cm)  Mean (cm) 
Fletcher’s 3-channel  2.5  2.5  2.5 
Uterine tandem with vaginal cylinder  2.0  2.0  2.0 
 